Share price · AMGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AMGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Sep 2026+4.3%
- 8 Sep 2026-10.1%
- AstraZeneca: AstraZeneca: IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNGAZN -1.6%
- 5 Aug 2026+4.6%
- 4 Aug 2026+2.9%
- 11 Jun 2026+4.8%
Nothing announced by AMGN that day or the session before.
- 3 Jun 2026+3.0%
- 15 May 2026-3.0%
Nothing announced by AMGN that day or the session before.
- 1 May 2026-4.7%
- 4 Feb 2026+8.2%
Share of unusual movement by asset
For each asset, the share of AMGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(29 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | VEGF-AProtein / enzyme therapeutic | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
apremilast(Otezla) | Approved | PDE4Small molecule | Psoriatic ArthritisPsoriasis |
bevacizumab-awwb(MVASI) | Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer |
| Approved | CD19 x CD3Multispecific antibody | Systemic Lupus ErythematosusRheumatoid ArthritisAcute Lymphoblastic Leukemia | |
| Approved | ProteasomeSmall molecule | Multiple Myeloma | |
| Approved | RANKLMonoclonal antibody | Rheumatoid ArthritisOsteoporosis | |
| Approved | CGRP receptorMonoclonal antibody | Migraine | |
etanercept(Enbrel) | Approved | TNF-alpha · TNF-alpha / TNF-beta (lymphotoxin-alpha)Protein / enzyme therapeutic | Psoriatic ArthritisPsoriasisRheumatoid Arthritis |
Etelcalcetide(Parsabiv) | Approved | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPeptide | Chronic Kidney Disease Secondary Hyperparathyroidism |
Evolocumab(Repatha) | Approved | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia |
| Approved | CD19Monoclonal antibody | Systemic Lupus ErythematosusMyasthenia Gravis Generalized Myasthenia Gravis | |
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease | |
Ivabradine(Corlanor) | Approved | If (funny) channelSmall molecule | Heart Failure |
| Approved | KRAS G12CSmall molecule | Non-Small Cell Lung CancerColorectal Cancer Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer |
Discontinued programmes (2)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(51 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (19)
January 2027 (3)
April 2027 (3)
June 2027 (4)
July 2027 (1)
What to watch
August 2027 (3)
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (14)
January 2028 (2)
What to watch
February 2028 (1)
What to watch
March 2028 (3)
May 2028 (1)
What to watch
June 2028 (3)
What to watch
What to watch
What to watch
July 2028 (1)
August 2028 (1)
What to watch
September 2028 (2)
What to watch
2029 (6)
January 2029 (2)
March 2029 (2)
August 2029 (1)
What to watch
September 2029 (1)
What to watch
2030 (4)
February 2030 (1)
What to watch
March 2030 (1)
What to watch
2031 (6)
March 2031 (1)
What to watch
June 2031 (1)
What to watch
July 2031 (1)
What to watch
September 2031 (1)
What to watch
October 2031 (1)
December 2031 (1)
What to watch
2036 (1)
March 2036 (1)
What to watch
Regulatory and conference events
(17)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 17 past events are shown.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $10.4B | $2.1B | $13.2B | —$4.2B operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $10.1B | $1.9B | $14.0B | —$4.0B operating cash flow | report ↗ |
| 2026-Q1 | $8.6B | $1.7B | $12.0B | —$2.2B operating cash flow | report ↗ |
| 2025-Q3 | $9.6B | $1.9B | $9.4B | —$4.7B operating cash flow | report ↗ |
| 2025-Q2 | $9.2B | $1.7B | $8.0B | —$2.3B operating cash flow | report ↗ |
| 2025-Q1 | $8.1B | $1.5B | $8.8B | —$1.4B operating cash flow | report ↗ |
| 2024-Q3 | $8.5B | $1.4B | $9.0B | —$3.6B operating cash flow | report ↗ |
| 2024-Q2 | $8.4B | $1.4B | $9.3B | —$2.5B operating cash flow | report ↗ |
| 2024-Q1 | $7.4B | $1.3B | $9.7B | $113M$689M operating cash flow | report ↗ |
| 2023-Q3 | $6.9B | $1.1B | $34.7B+ $0 short-term inv. | —$2.8B operating cash flow | report ↗ |
| 2023-Q2 | $7.0B | $1.1B | $34.2B+ $0 short-term inv. | —$4.1B operating cash flow | report ↗ |
| 2023-Q1 | $6.1B | $1.1B | $31.6B+ $1.0M short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2022-Q3 | $6.7B | $1.1B | $9.5B+ $2.0B short-term inv. | —$3.0B operating cash flow | report ↗ |
| 2022-Q2 | $6.6B | $1.0B | $5.2B+ $2.0B short-term inv. | —$1.9B operating cash flow | report ↗ |
| 2022-Q1 | $6.2B | $959M | $6.5B+ $16M short-term inv. | —$2.2B operating cash flow | report ↗ |
| 2021-Q3 | $6.7B | $1.4B | $12.0B+ $952M short-term inv. | —$2.4B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $36.8B | $7.3B | $9.1B | —$10.0B operating cash flow | report ↗ |
Amgen reported full-year 2025 total revenues of $36,751M, up 10.0% YoY, with research and development spend of $7,272M, up 21.9% YoY. Cash and equivalents stood at $9,129M, and the company reported net income of $7,711M for the year.
For 2026, Amgen guided total revenues of $37.0B to $38.4B, GAAP EPS of $15.45 to $16.94, non-GAAP EPS of $21.60 to $23.00, capital expenditures of approximately $2.6B, and share repurchases not exceeding $3B. Pipeline updates included ongoing Phase 3 MariTide studies for obesity and type 2 diabetes, full FDA approval of IMDELLTRA in extensive-stage small cell lung cancer, new UPLIZNA approvals in IgG4-related disease and generalized myasthenia gravis, and a disclosed FDA request to voluntarily withdraw TAVNEOS from the U.S. market, which Amgen stated it did not intend to follow.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $33.4B | $6.0B | $12.0B | —$11.5B operating cash flow | report ↗ |
| 2023-FY | $28.2B | $4.8B | $10.9B+ $0 short-term inv. | —$8.5B operating cash flow | report ↗ |
| 2022-FY | $26.3B | $4.4B | $7.6B+ $1.7B short-term inv. | —$9.7B operating cash flow | report ↗ |
| 2021-FY | $26.0B | $4.8B | $8.0B+ $48M short-term inv. | —$9.3B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($25.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Drake Michael V · director | Award / grant | 114.026 | — | — | Form 4 |
| 2026-11-06 | Gibbs David W · director | Award / grant | 278 | — | — | Form 4 |
| 2026-11-06 | HOLLEY CHARLES M · director | Award / grant | 184.614 | — | — | Form 4 |
| 2026-11-06 | ISHRAK OMAR · director | Award / grant | 152.035 | — | — | Form 4 |
| 2026-08-13 | Khosla Rachna · SVP, Business Development | Option exercise | 1,252 | $162.60 | $204K | Form 4 |
| 2026-08-13 | Khosla Rachna · SVP, Business Development | Open-market sale | 1,252 | $416.43 | $521K | Form 4 |
| 2026-08-13 | Khosla Rachna · SVP, Business Development | Option exercise (derivative) | 1,252 | — | — | Form 4 |
| 2026-08-11 | Khosla Rachna · SVP, Business Development | Open-market sale | 2,000 | $412.57 | $825K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,103 reporting institutions held 428.0M shares ($146.9B, 79.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 47,100,472 | $16.6B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 35,014,232 | $12.3B |
| 3 | STATE STREET CORP | 30,548,488 | $10.7B |
| 4 | Capital World Investors | 29,288,343 | $10.3B |
| 5 | MORGAN STANLEY | 15,836,058 | $5.6B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 15,430,524 | $5.4B |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 14,621,148 | $5.1B |
| 8 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 12,773,386 | $4.5B |
| 9 | PRIMECAP MANAGEMENT CO/CA/ | 8,874,129 | $3.1B |
| 10 | JPMORGAN CHASE & CO | 7,277,837 | $2.5B |
| 11 | Capital International Investors | 7,122,275 | $2.5B |
| 12 | WELLS FARGO & COMPANY/MN | 7,088,010 | $2.5B |
| 13 | Capital Research Global Investors | 6,955,345 | $2.4B |
| 14 | NORTHERN TRUST CORP | 6,217,838 | $2.2B |
| 15 | BANK OF AMERICA CORP /DE/ | 5,121,028 | $1.8B |